| abstract |
The present invention relates to non-real antihistamines, excluding loratadine-based compounds, a leukotriene antagonist selected from the group consisting of a leukotriene D 4 antagonist, a 5-lipoxygenase inhibitor and a FLAP antagonist, and optionally a physiologically acceptable excipient, Disclosed are pharmaceutical formulations for topical or case administration to prevent or treat allergic or vasomotor rhinitis or allergic conjunctivitis in combination with extenders and adjuvants. |